MeiraGTx HoldingsSTU:328 56 Buyback Yield % is -0.50 as of Jul. 06, 2026. GuruFocus rates STU:328 with a GF Score™ of 56/100 and a GF Value™ of €20.56 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 741 Biotechnology companies, MeiraGTx Holdings ranks better than 75.44% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for MeiraGTx Holdings's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:328 vs XNCR, WVE, CGEM: Buyback Yield % Comparison
For the Biotechnology subindustry, MeiraGTx Holdings's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MeiraGTx Holdings Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MeiraGTx Holdings's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where MeiraGTx Holdings's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MeiraGTx Holdings (STU:328) has a Buyback Yield % of -0.50 as of Jul. 06, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on MeiraGTx Holdings and its competitors. According to the industry distribution chart, MeiraGTx Holdings ranks #182 out of 741 companies in the Biotechnology industry, placing it in the top 24.6%.
Is MeiraGTx Holdings' Buyback Yield % too high?
MeiraGTx Holdings' current Buyback Yield % is -0.50. Based on the distribution chart, MeiraGTx Holdings ranks #182 out of 741 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MeiraGTx Holdings has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MeiraGTx Holdings' Buyback Yield % compare to XNCR and WVE?
According to the Biotechnology industry distribution chart, MeiraGTx Holdings ranks #182 out of 741 companies for Buyback Yield %. This places MeiraGTx Holdings in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on MeiraGTx Holdings and its competitors. MeiraGTx Holdings's current Buyback Yield % is -0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeiraGTx Holdings stock overvalued right now?
Based on GuruFocus' analysis, MeiraGTx Holdings (STU:328) is currently considered Possible Value Trap. The stock's GF Value™ is €20.56, compared to a current price of €12.10 — trading 41.1% below its estimated fair value. The current Buyback Yield % is -0.50. MeiraGTx Holdings' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For MeiraGTx Holdings (STU:328), the current Buyback Yield % is -0.50 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MeiraGTx Holdings (STU:328) Overvalued in 2026?
Based on GuruFocus' analysis, MeiraGTx Holdings stock appears to be undervalued.
The current stock price of €12.10 is trading 41.1% below its estimated GF Value™ of €20.56.
GuruFocus considers MeiraGTx Holdings to be Possible Value Trap.
Key valuation signals for STU:328:
Buyback Yield %: -0.50
GF Value™: €20.56 vs. price of €12.10 (41.1% below fair value)
No single metric tells the full story. See the STU:328 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
56GF Score
Get the complete analysis for STU:328
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:328 has been successfully added to your 
